Fate Therapeutics (FATE) Misses Q3 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.31), $0.06 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.87 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MIND Technology (MIND) Misses Q1 EPS by 5c
• Independent Bank receives regulatory approval for HCB Financial acquisition